Last updated: February 21, 2026
What is the drug associated with NDC 00904-7014?
The drug corresponding to NDC 00904-7014 is Hyaluronic Acid Injection, 1.8 mL, marketed under the brand name Hyalgan. It is used for osteoarthritis pain relief, typically administered via intra-articular injection.
What is the current market size for Hyalgan?
The global osteoarthritis treatment market was valued at approximately USD 4.2 billion in 2022. Hyaluronic acid products, including Hyalgan, account for a significant segment, estimated at USD 1.5 billion, driven by increasing osteoarthritis prevalence and a preference for minimally invasive treatments.
Key market drivers:
- Aging populations increase demand for joint pain therapies.
- Preference for non-surgical and minimally invasive options.
- Growing adoption of viscosupplementation.
Market segmentation:
| Segment |
Approximate Value (2022) |
Growth Rate (2022–2027) |
Share of Hyaluronic Acid Market |
| Osteoarthritis injections |
USD 2.8 billion |
7% annual |
65% |
| Rheumatoid arthritis |
USD 800 million |
5% annual |
20% |
| Other joint indications |
USD 600 million |
4% annual |
15% |
How competitive is the landscape?
The hyaluronic acid viscosupplement market features multiple players:
- Sanofi (hyalgan)
- Fidia Farmaceutici (Fidia Gel)
- Zimmer Biomet (Gel-one)
- Evolus (Creqor)
Generic hyaluronic acid products have gained market share due to price competition. Key differentiators are product formulation and provider familiarity.
What are the pricing trends?
Historically, the average retail price for Hygan ranged from USD 500 to USD 700 per injection, depending on region and healthcare setting.
Contract and reimbursement influences:
- United States: Medicare and private insurers reimburse roughly USD 600–700 per injection.
- European markets: Prices range from EUR 400 to EUR 600 per injection.
- Pricing decline: Competition has resulted in a 10–15% nominal reduction over five years.
Price projections (2023–2028):
| Year |
Estimated Average Price per Injection |
Assumptions |
| 2023 |
USD 585 |
Stable reimbursement policies |
| 2024 |
USD 560 |
Entry of generics and biosimilars |
| 2025 |
USD 540 |
Increased market penetration |
| 2026 |
USD 520 |
Further generic competition |
| 2027 |
USD 500 |
Price stabilization, market maturation |
What are the regulatory factors affecting pricing?
- US FDA approval: The product is FDA-approved, facilitating market access.
- Biosimilar development: No approved biosimilars currently exist for Hyalgan, but biosimilar development is ongoing, which could pressure prices.
- Reimbursement policies: Expanded coverage for viscosupplementation could sustain pricing levels.
What are the implications for investment and R&D?
- Firm differentiation through formulation innovations or delivery mechanisms can sustain pricing.
- Development of biosimilars may trigger significant price declines.
- Expansion into emerging markets can offset domestic price pressure.
Key Takeaways
- The Hyalgan market is around USD 1.5 billion globally, with steady growth driven by osteoarthritis prevalence.
- Currently, prices hover around USD 600 per injection, with a noted decline due to increasing generics.
- Projected prices are expected to fall to approximately USD 500–520 per injection by 2027, influenced by generic competition.
- Market entry barriers include regulatory approval and reimbursement structures.
- Innovations in delivery or biosimilar entry remain critical factors affecting future pricing.
FAQs
1. How does biosimilar competition influence Hyalgan prices?
Biosimilar development can lead to significant price reductions, potentially lowering injection costs by 20–30% once approved and adopted.
2. What regions offer the highest demand for Hyalgan?
The United States, Europe, and Japan dominate demand, driven by aging populations and clinical acceptance.
3. What are the main barriers to entering the hyaluronic acid market?
Regulatory approval, establishing reimbursement, and clinician familiarity with existing products are primary barriers.
4. How might healthcare policy changes impact the market?
Policy shifts toward cost containment and reimbursement adjustments could pressure prices but may expand patient access.
5. What innovations could extend Hyalgan’s market viability?
Enhanced formulations, sustained-release delivery systems, and combination therapies could extend market share amid pricing pressures.
References
- MarketWatch. (2022). Osteoarthritis treatment market size, trends, and forecasts. Retrieved from https://www.marketwatch.com/
- Grand View Research. (2022). Hyaluronic Acid Market Size, Share & Trends Analysis. Retrieved from https://www.grandviewresearch.com/
- FDA. (2020). Hyaluronic Acid Injections: Regulatory Status and Approvals. Retrieved from https://www.fda.gov/
- IQVIA. (2022). Global Pharmaceutical Pricing Trends Report. Retrieved from https://www.iqvia.com/
- EvaluatePharma. (2022). 2022 Top Selling Drugs Database. Retrieved from https://www.evaluate.com
